Current use of bispecific antibodies to treat mul ti ple mye loma

Official Consumer Website | TECVAYLI® (teclistamab-cqyv)

TECVAYLI® is the first treatment of its kind for multiple myeloma—it's called a bispecific antibody , and it works by binding to both multiple myeloma cells as ...

Using the available repertoire of bispecific antibodies for treating ...

... bispecific antibodies available for treating multiple myeloma (MM) and suggests how they can be incorporated into the current treatment paradigm

Bispecific Antibodies: Early Side Effects

Bispecific antibodies are a promising treatment for myeloma, but they can cause early side effects, including cytokine release syndrome (CRS) and immune ...

Bispecific Antibody Combos for R/R Myeloma: What to Know

Tara Gregory, MD, explains what bispecific antibody combinations have been approved for relapsed/refractory multiple myeloma, potential side ...

T-cell redirecting bispecific and trispecific antibodies in

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA · Abstract · INTRODUCTION · TARGETING G-PROTEIN-COUPLED RECEPTOR CLASS 5 ...

Powerful new therapy doubles treatment targets - City of Hope

Teclistamab, a bispecific antibody recently approved by the Food and Drug Administration (FDA) for multiple myeloma, is currently being used in ...

Multiple myeloma: Treatment of second or later relapse - UpToDate

Outline · Targeting BCMA · - Chimeric antigen receptor T cells · Clinical use · Efficacy · Toxicity · - Bispecific antibodies · Clinical use ...

Optimizing Bispecific Antibody Therapy in Multiple Myeloma

Bispecific antibodies that target both an antigen expressed on the surface of effector cells and a tumor-associated antigen are one of the novel antibody ...

Talquetamab in multiple myeloma - Haematologica

It demonstrated a similar efficacy profile and durability of response to teclistamab, the first bispecific antibody therapy to be approved in ...

Management of Adverse Effects in Patients With Multiple Myeloma ...

For patients with RRMM, BsAbs represent a new treatment option, with several now approved by the US Food and Drug Administration (FDA) and more ...

T-Cell Redirecting Bispecific Antibodies for MM Treatment

BsAbs are promising new agents that harness the power of T cells to eliminate MM cells. Recent data demonstrated that these novel therapies for ...

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

Treatment with bispecific antibodies (bsAbs) is an immunotherapeutic strategy that leads to an enhanced interaction between MM cells and immune ...

What Myeloma Patients Need to Know About Bispecific Antibodies

That's the treatment. And the bispecific antibodies that I often call T-cell redirecting antibodies, because they redirect the T cells to the ...

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for ...

The first bispecific antibody (bsAb) for the treatment of relapsed/refractory multiple myeloma (RRMM), teclistamab, has been approved in 2022.

Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody ...

... Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma ... multiple myeloma who present to the emergency department for care. Learning ...

T-cell redirecting bispecific antibodies targeting BCMA ... - Oncotarget

Immunotherapeutic agents are increasingly used for the treatment of both newly diagnosed and relapsed/refractory multiple myeloma (MM) patients ...

Pre-test | Novel Mechanisms and Therapeutic Targets in Relapsed ...

Bispecific antibodies are an emerging immunotherapy modality under clinical investigation for relapsed/refractory multiple myeloma.

Current status of drug development for patients with multiple myeloma

ADCs improve the efficacy of naked antibodies, performing targeted delivery of highly cytotoxic chemotherapy to malignant cells. Compared with other antibody- ...

Your questions about BCMA and multiple myeloma, answered

BCMA stands for B cell maturation antigen, and it's emerged as an important target in multiple myeloma over the last five years or so.

Monoclonal antibodies for the treatment of multiple myeloma

There are also evidence reports to suggest bispecific antibodies could be effective for patients with high-risk disease, although more ...